Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321932 · ClinicalTrials.gov registry record · Phase 2
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00321932 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 61 participants.
The verdict
NCT00321932, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant. PURPOSE: This randomized phase II trial is studying how well zoledronic acid works in preventing osteoporosis in patients undergoing donor stem cell transplant.
Interventions
- DRUG zoledronic acid
- DIETARY_SUPPLEMENT cholecalciferol
- DIETARY_SUPPLEMENT calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2005-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321932
The ClinicalTrials.gov registry entry for NCT00321932 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which zoledronic acid is the first listed.
NCT00321932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321932 about?
NCT00321932 is a clinical study titled "Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant". RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant. PURPOSE: This randomized phase II trial is studying how well zoledronic acid works in preventing osteoporosis in patients undergoing donor stem cell transplant.
What is the current status of trial NCT00321932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2005-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00321932?
The interventions under investigation include: zoledronic acid (DRUG), cholecalciferol (DIETARY_SUPPLEMENT), calcium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00321932?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.